Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of batoclimab in thyroid eye disease
MOH_2023-06-14_012743Phase 3Completed
- Sponsor
- Immunovant, Inc.
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of batoclimab in Graves Orbitopathy (GO) (2 cohorts), sponsored by Immunovant, Inc. Primary endpoint: Maintenance of efficacy by proptosis assessment. Started May 2023; status: completed.
02
Drugs
batoclimab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on MOH_2023-06-14_012743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-06-14_012743.